Get the Stockscreener App
0.00
100.00%
-0.1426
After Hours:
.11
0.11
+
Omega Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
See More
Previous Close:
$0.1426
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$7.90M
Revenue:
$3.10M
Net Income/Loss:
$-97.43M
P/E Ratio:
0.00
EPS:
-1.8
Net Cash Flow:
$-94.38M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$3.00
Omega Therapeutics Inc Stock (OMGA) Company Profile
Name
Omega Therapeutics Inc
Sector
Industry
Phone
(617) 949-4360
Address
140 FIRST STREET, SUITE 501, CAMBRIDGE
Compare OMGA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMGA
Omega Therapeutics Inc
|
0.00 | 7.90M | 3.10M | -97.43M | -94.38M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Omega Therapeutics Inc Stock (OMGA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-18-24 | Initiated | Raymond James | Outperform |
| May-25-23 | Resumed | Jefferies | Buy |
| Dec-08-22 | Initiated | H.C. Wainwright | Buy |
| Sep-23-22 | Initiated | Chardan Capital Markets | Buy |
Omega Therapeutics Inc Stock (OMGA) Latest News
Omega Therapeutics (NASDAQ:OMGA) Trading Down 21.8% – Time to Sell? - Defense World
Biotech Firm Omega Therapeutics OK'd For $14M Ch. 11 Sale - Law360
Layoff Tracker: Tempest Axes 80% of Workforce - BioSpace
Recursion Pharmaceuticals (NASDAQ:RXRX) & Omega Therapeutics (NASDAQ:OMGA) Critical Analysis - Defense World
OMEGA THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Omega Therapeutics (OMGA) Projected to Post Earnings on Thursday - The AM Reporter
Omega Therapeutics (OMGA) to Release Quarterly Earnings on Thursday - Defense World
Flagship's Empress lays off 53% of staffers in push to get science to clinic - Fierce Biotech
Omega Therapeutics secures $9.8M in DIP financing - MSN
Programmable mRNA therapeutics for controlled epigenomic modulation of single and multiplexed gene expression in diverse diseases - Nature
Lila Sciences raises $200M to accelerate autonomous scientific research - SiliconANGLE
HilleVax (NASDAQ:HLVX) & Omega Therapeutics (NASDAQ:OMGA) Critical Survey - Defense World
Struggling healthcare firm files for Chapter 11 bankruptcy - TheStreet
Petri Dish: Bankrupt Flagship firm sells assets; Nimbus hits milestone - The Business Journals
OMEGA THERAPEUTICS INC Revenue Breakdown – OTC:OMGAQ - TradingView
Two new option listings and eighteen option delistings on February 25th - TipRanks
Omega Therapeutics to sell assets amid Nasdaq delisting By Investing.com - Investing.com India
Omega Therapeutics to sell assets amid Nasdaq delisting - Investing.com
Intrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & Immunology - GlobeNewswire
Volcon, Inc. and GlucoTrack, Inc. See Massive Gains, While Omega Therapeutics and Universe Pharmaceuticals Struggle - HPBL
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Omega Therapeutics Inc Stock (OMGA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):